Search
Print Page   |   Contact Us   |   Sign In   |   Join Today
News & Press: Company News

Neoantigenics Announces Collaboration with Pfizer, Investment from CIT

Thursday, January 30, 2014  
Share |

Neoantigenics LLC, a new biotechnology company founded on discoveries made by Dr. John Herr at the University of Virginia School of Medicine, has entered into an early-stage research and development collaboration with Pfizer Inc.

 

The collaboration is focused on the development of antibody-based therapeutics and companion diagnostics targeting Neoantigenics’ proprietary oocyte-associated biomarkers, which are selectively expressed on a wide array of human cancers.

 

In addition to scientific engagement between Neoantigenics and Pfizer’s scientific teams, Pfizer is making an equity investment in Neoantigenics through the Pfizer Seed Fund, which supports promising early-stage life science companies. The investment is part of a round that included an investment from the Center for Innovative Technology’s GAP Fund and an award from the Commonwealth Research Commercialization Fund.

 

"Our collaboration with Pfizer supports the unique foundational science behind Neoantigenics, and demonstrates an innovative way for start-ups like us to effectively work with a leading pharmaceutical company,” said Brian A. Pollok, founding CEO for Neoantigenics and Entrepreneur-in-Residence at U.Va. Innovation.

 

"UVA Innovation is pleased to have worked with Pfizer, CIT, Neoantigenics’ management and with Dr. Herr to help create a unique funding model to launch this company,” said Michael P. Straightiff, director of U.Va. Licensing & Ventures Group.

 

Herr, Neoantigenics’ scientific founder and inventor of oocyte-associated cancer targets, said the partnership with Pfizer is an important step in further advancing research that his School of Medicine team began in the 1990s.

 

"Our discovery of oocyte-specific membrane proteins, coupled with an understanding that certain cancers express genes normally restricted to growing eggs, provides Neoantigenics with a platform strategy to develop biological drugs that are tumor-selective,” he said.

 


more Events

9/29/2016
MDMA 2016 Medical Technology Executive Forum

9/29/2016
Women Building Bio: The XX Factor

Premium Members

Membership Software Powered by YourMembership.com®  ::  Legal